Skip to content

John H. Halpern

13 papers in the library · 1,436 citations · publishing 1996-2018

Papers

Sort Most recent Most cited

A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.

Current Topics in Behavioral Neurosciences 2018 John H. Halpern, Arturo G Lerner, Torsten Passie

Hallucinogen persisting perception disorder (HPPD) is rarely encountered in clinical settings. It is described as a re-experiencing of some perceptual distortions induced while intoxicated and suggested to subsequently cause functional impairment or anxiety. Two forms exist: Type 1, which are brief "flashbacks," and Type 2 claimed to be chronic, waxing, and waning over months to years. A review...

DOI: 10.1007/7854_2016_457 (opens in new tab) Full text (opens in new tab) LSD Dissociation Drug-induced flashback Hallucinogens

The association of psychedelic use and opioid use disorders among illicit users in the United States.

Journal of Psychopharmacology May 2017 Vincent D Pisano, Nathaniel P Putnam, Hannah M. Kramer et al.

Preliminary studies show psychedelic compounds administered with psychotherapy are potentially effective and durable substance misuse interventions. However, little is known about the association between psychedelic use and substance misuse in the general population. This study investigated the association between psychedelic use and past year opioid use disorders within illicit opioid users....

Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting.

The Journal of Nervous and Mental Disease July 2016 Vicka Rael Corey, Vincent D Pisano, John H. Halpern

3,4-Methylenedioxymethamphetamine (MDMA) administered as an adjunct to talk therapy influences patient speech content and increases improvement in treatment-resistant posttraumatic stress disorder (PTSD). Data came from the recordings of Mithoefer et al. (2011). In the third therapeutic session studied, patients were assigned, double blind, to an MDMA or a placebo group. Condition-blind scorers...

Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence

Drug Testing and Analysis June 26, 2012 Torsten Passie, Hinderk M. Emrich, Matthias Karst et al. 114 citations

It is known from clinical studies that some patients attempt to cope with the symptoms of post-traumatic stress disorder (PTSD) by using recreational drugs. This review presents a case report of a 19-year-old male patient with a spectrum of severe PTSD symptoms, such as intense flashbacks, panic attacks, and self-mutilation, who discovered that some of his major symptoms were dramatically...

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series

Cephalalgia March 26, 2010 Matthias Karst, John H. Halpern, Michael Bernateck et al. 104 citations

Cluster headache (CH) is a stereotyped primary headache characterized by strictly unilateral severe orbital or periorbital pain and categorized as either episodic or chronic (1,2). Its prevalence is 0.1% (3). Oxygen and sumatriptan are the treatments of choice for individual attacks, whereas verapamil, lithium, corticosteroids and other neuromodulators can suppress attacks during cluster...

The Pharmacology of Lysergic Acid Diethylamide: A Review

CNS Neuroscience & Therapeutics November 11, 2008 Torsten Passie, John H. Halpern, Dirk O. Stichtenoth et al. 459 citations

Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as an experimental drug in psychiatric research for producing so‐called “experimental psychosis” by altering neurotransmitter system and in psychotherapeutic procedures (“psycholytic” and “psychedelic” therapy). From the mid 1960s, it became an illegal...

DOI: 10.1111/j.1755-5949.2008.00059.x (opens in new tab) Lysergic acid diethylamide Psychopharmacology Consciousness Clinical pharmacology +3

Response of cluster headache to psilocybin and LSD

Neurology June 26, 2006 R. Andrew Sewell, John H. Halpern, Harrison G. Pope 259 citations

The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on...

DOI: 10.1212/01.wnl.0000219761.05466.43 (opens in new tab) Ipilimumab Nivolumab Demographics Adverse effect +4

Psychological and cognitive effects of long-term peyote use among Native Americans.

Biological Psychiatry October 15, 2005 John H. Halpern, Andrea R Sherwood, James I. Hudson et al. 186 citations

Hallucinogens are widely used, both by drug abusers and by peoples of traditional cultures who ingest these substances for religious or healing purposes. However, the long-term residual psychological and cognitive effects of hallucinogens remain poorly understood. We recruited three groups of Navajo Native Americans, age 18-45: 1) 61 Native American Church members who regularly ingested peyote,...

Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs.

Drug and Alcohol Dependence August 16, 2004 John H. Halpern, Harrison G. Pope, Andrea R Sherwood et al.

A substantial literature suggests that users of illicit 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") display residual cognitive deficits. Most MDMA users, however, use other illicit drugs as well, so it is difficult to be certain that these deficits are due to MDMA, as opposed to other drug use or additional confounding factors. We administered a battery of neuropsychological tests to...

Hallucinogens and dissociative agents naturally growing in the United States.

Pharmacology & Therapeutics May 1, 2004 John H. Halpern 209 citations

It is usually believed that drugs of abuse are smuggled into the United States or are clandestinely produced for illicit distribution. Less well known is that many hallucinogens and dissociative agents can be obtained from plants and fungi growing wild or in gardens. Some of these botanical sources can be located throughout the United States; others have a more narrow distribution. This article...

DOI: 10.1016/j.pharmthera.2004.03.003 (opens in new tab) Full text (opens in new tab) Ayahuasca Natural hallucinogens Psychedelic plants Entheogenic fungi +23

Hallucinogens: an update.

Current Psychiatry Reports October 1, 2003 John H. Halpern 42 citations

Research of hallucinogen abuse rarely extends beyond epidemiology and observed pathology. Even less research has been completed on the special circumstances surrounding the religious use of hallucinogens or on potential therapeutic applications. Rather than offer another basic review on the well-known hazards of illicit hallucinogen use, this paper provides an overview and practice...

DOI: 10.1007/s11920-003-0067-4 (opens in new tab) Full text (opens in new tab) Psychoactive substances: entheogens Mind-altering compounds Novel compounds Nonaddictive compounds +13

Hallucinogen persisting perception disorder: what do we know after 50 years?

Drug and Alcohol Dependence March 1, 2003 John H. Halpern, Harrison G. Pope

'Flashbacks' following use of hallucinogenic drugs have been reported for decades; they are recognized in DSM-IV as 'Hallucinogen Persisting Perception Disorder (Flashbacks)', or HPPD. We located and analyzed 20 quantitative studies between 1955 and 2001 examining this phenomenon. However, many of these studies were performed before operational criteria for HPPD were published in DSM-III-R, so...

The Use of Hallucinogens in the Treatment of Addiction

Addiction Research & Theory 1996 John H. Halpern 63 citations

AbstractResearch into treating drug dependence with hallucinogens, although promising, ended with questions still unanswered because of varying, in some cases skeptical, methodology and insufficient adherence to a double-blind, placebo-controlled design. Interest is again emerging, especially with the recent patenting in the United States of ibogaine for its apparent anti-craving properties. A...